Please assess the completion status of the following clinical trial:

Trial Title: Safety & Efficacy Study of Gemcitabine...With High Dose IV Vit. C (HDIVC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient ≥ 18 years of age~* Biopsy proven adenocarcinoma of the pancreas~* Evidence of metastatic disease~* Received at least 1 prior chemotherapy treatment regimen with disease progression~* May have had any prior chemotherapy regimen including any gemcitabine based regimen or FOLFIRINOX~* May have participated in a prior study protocol~* May have had prior treatment with HDIVC~* Anticipated survival of at least 3 months~* Eastern Cooperative Oncology Group (ECOG) performance status = 0,1, or 2~* The patient must have screening laboratory: ANC ≥ 1,500/mm3, Hemoglobin \> 8g/dL, Platelets ≥ 100,000/mm3, Total Bilirubin \< 1.5mg/dL, Creatinine ≤ 1.5mg/dL, Transaminases \< 2.5 x upper limit of normal, Urine Uric Acid \< 1.000 mg/d, Urine pH \< 6, Urine microscopic negative for oxalates (if positive, reflex urinary oxalates \< 60mg/d), PT INR ≤ 1.5, unless patient is on full dose warfarin~* Glucose-6-phosphate dehydrogenase deficiency (G6PD) normal status via blood test The fluorescent spot test is the simplest, most reliable, and most sensitive of the G6PD screening tests~* Willingness to undergo central line placement and able to manage care of the entry site safely~* Willingness to adhere to supplemental oral dose regimen of ascorbic acid 500mg taken twice daily~* All other nutritional supplements would be discontinued for the duration of the trial except for pancreatic enzymes and probiotics~* Patients must be able to take food orally or have a peg tube for feeding~* Able to give consent for protocol participation~Exclusion Criteria:~* Glucose-6-phosphate dehydrogenase deficiency (G6PD)~* Renal insufficiency : serum creatinine of \> 1.5 mg /dl or evidence of oxalosis by urinalysis prior to enrollment and prior to each HDIVC infusion~* Documentation or report of history of kidney stones or urinary oxalosis.~* Co-morbid condition that would affect survival: congestive heart failure, unstable angina, myocardial infarction within 6 weeks of study, uncontrolled blood sugars of \> 300 mg / dl, patients with known chronic active hepatitis or cirrhosis~* Currently active second malignancy~* Chronic hemodialysis~* Iron overload/ Hemochromatosis: Ferritin \> 500 ng / ml~* Wilson's disease~* Pregnant or lactating female (pre- menopausal females will undergo pregnancy test prior to administration of protocol drugs throughout treatment cycles during this study)~* Aspirin use exceeding 81 mg per day~* Acetaminophen use exceeding 2 g per day~* Known brain metastasis~* Active tobacco smokers~* Treatment with the combination of HDIVC and gemcitabine previously

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HDIVC (Type: EXPERIMENTAL): Gemcitabine (Gemzar), Intravenous and oral Ascorbic Acid (Vitamin C).

Based on this trial design, predict the completion outcome and termination type (if applicable).